RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group - Gilde Healthcare

Menu
Menu
Home

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

January 19, 2021

Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group.

Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in and around Lahnstein and provide imaging services to several local hospitals.

RAD-x is pleased to see its Partnership model confirmed by the integration of RZL and expects to further accelerate the growth of its platform structure in 2021.

 

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

More news

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
February 6, 2026

Gilde Healthcare appoints Matthew Stork as CEO and Maarten Jaspers as Finance Director of its neuroimaging technology group

The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director. Matthew Stork has over 25...
February 5, 2026

Gilde Healthcare Company Volta Medical publishes RESTART Trial Results on AI Solutions in Recurrent Atrial Fibrillation

Volta Medical’s artificial intelligence (AI) solution demonstrated 83% freedom from atrial fibrillation (AF) at 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins following prior ablation Volta Medical, committed...
February 3, 2026